On Dec. 14. 2019, Nanomix announced that the company had received CE Mark for its S1 Assay for the rapid, simultaneous detection and quantification of lactate, procalcitonin, and C-reactive protein from human plasma specimens.

Nanomix developed the S1 Assay to aid in the rapid detection of serious infections, including sepsis and bacteremia.